Medicare announced 15 lower drugs after a second round of negotiations with pharmaceutical companies. The drugs include ...

The Trump administration’s negotiation with Novo Nordisk A/S that slashes 71% off the list price of its blockbusters Ozempic ...

In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.

The U.S. Centers for Medicare and Medicaid Services (CMS) on Tuesday announced that it has secured lower prices for 15 of its ...

Shares of Novo Nordisk ($NVO) are up 3% at the time of writing after the Centers for Medicare & Medicaid Services (CMS) ...

The US government said Tuesday it negotiated a 71% discount off of the list price of Novo Nordisk A/S’s blockbuster drugs ...

Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the Inflation Reduction ...

Medicare has negotiated steep new prices for 15 high-cost drugs, including Novo Nordisk’s blockbuster semaglutide (Wegovy and Ozempic), with negotiated prices set to take effect in 2027. The move cuts ...

How drugs were selected: Drugs were selected earlier this year based on criteria written into the law. They had to have no ...

Novo Nordisk is using its ticket for an extra-speedy regulatory review granted through the FDA’s Commissioner’s National ...

CMS has negotiated a 71% discount off the list price, or $274 for a 30-day supply, on Novo Nordisk’s semaglutide products — Ozempic and Rybelsus for diabetes and Wegovy for weight loss — through the ...

The Trump administration late Tuesday announced new lower Medicare prices for 15 drugs that were part of the latest round ...